A total of 1,800 blood specimens (1,000 from healthy blood donors, 300 from patients with sexually transmitted diseases, and 500 from intravenous drug users) were simultaneously tested with anti-human immunodeficiency virus enzyme-linked immunosorbent assay (ELISA) kits and a newly developed 2-min test for anti-human immunodeficiency virus based on the principle of autologous erythrocyte agglutination (AGEN Biomedical Limited). We found that AGEN's rapid test was as sensitive and specific as the other ELISA kits.
Because of the serious medical and psychosocial impacts of human immunodeficiency virus (HIV) infection, a sensitive and specific test is essential to distinguish those who are infected from those who are not infected. This can be accomplished either by antigen (HIV) or antibody (anti-HIV) detection or identification (1, 9, 12) . Most of the screening assays are based on enzyme-linked immunosorbent assay (ELISA), which takes as long as 2 h to be completed and thus is not practical for emergency screening (4) . Therefore, many simple and rapid tests such as particle agglutination, hemagglutination, dot immunobinding assay, and dot enzyme immunoassay have been developed (2, 3, 6, 11, 13) . The most novel assay among these is an autologous erythrocyte agglutination test (AGEN Biomedical Limited, Brisbane, Queensland, Australia), which does not require the separation of serum or plasma and the results of which can be read within 2 min (8) without sophisticated equipment. The test takes advantage of a bivalent reagent that is a chemical conjugate of a monoclonal antibody to erythrocyte surface antigens (which by itself does not cause agglutination of erythrocytes) and a synthetic gp4l peptide (7, 10, 14) . The antibody to HIV type 1, if present in the blood sample, will bind to the peptide-antigen conjugate on the erythrocytes, causing cross-linking between erythrocytes that results in visible hemagglutination. The test has been extensively studied in three Australian blood banks (n = 5,160) and two Australian hospital clinics (n = 419); a specificity and a sensitivity of 99.7 and 100%, respectively, were found. A comparative study of this newly developed autologous erythrocyte agglutination test and the conventional commercial anti-HIV test kits was undertaken in three different laboratories serving three different patient populations in Thailand.
Three different groups of subjects were included in this study, namely, healthy blood donors from the National Blood Center, Thai Red Cross Society, Bangkok, Thailand (n = 1,000); intravenous drug users (IVDU) from Thanyarak * Corresponding author.
Hospital, Pathumthani Province, Thailand (n = 500); and patients with sexually transmitted diseases (STD) from the Venereal Disease Control Division, Department of Communicable Disease Control, Ministry of Public Health, Bangkok, Thailand (n = 300).
Five milliliters of blood was taken from each subject by venipuncture and divided equally into two tubes. One tube contained citrated blood for the anti-HIV autologous erythrocyte agglutination test, and the other contained clotted blood for anti-HIV ELISA. The two tests were performed independently at the laboratory where the specimens were obtained within 24 h of specimen collection.
The a The calculation was based on the assumption that any indeterminate immunoblots with a p24 band should be considered positive whereas all other indeterminates should be considered negative.
b The prevalence of HIV infection within a given population was low for blood donors, medium for STD patients, and high for IVDU.
c ELISA kits used were that of Abbott for blood donors, that of Organon for STD patients, and that of Roche for IVDU. sensitivity of 99.5 to 100% and a specificity of 99.6 to 100% ( Table 2) . These results are consistent with those reported from large laboratories in Australia (15) . The AGEN test results are comparable to results obtained for the other three ELISA kits simultaneously evaluated. Therefore, the use of this rapid test is quite appropriate for office practice and for emergency department screening. The AGEN test would be particularly useful for emergency screening of transfused blood as well as for field serosurvey because of its rapidity (2 min), its ease and simplicity (no need for washing or any sophisticated instruments), and its applicability with unclotted whole blood (such as from a finger prick). Nevertheless, as for all other screening tests, a supplemental or confirmatory test is still needed for any positive samples.
